Fact Meets Function

This research review examined the safety and efficacy evidence for peptide therapies used in musculoskeletal injuries and athletic performance, including BPC-157, finding limited clinical data to support many commonly used peptides. For medical practitioners selling peptide supplements, this highlights the importance of understanding the current evidence gaps and managing patient expectations regarding outcomes. For Annular and similar brands offering oral peptides to clinics, this research underscores the need for transparent communication about the preliminary nature of much peptide research when educating healthcare providers about their products.

This review article examines the potential therapeutic role of BPC 157, a 15-amino acid peptide, in treating severe electrolyte disturbances in rats (animal model evidence). The review synthesizes findings demonstrating that BPC 157 administration was associated with improvements in electrolyte balance and related physiological parameters in rat studies. The evidence presented is limited to animal model research and represents a summary of existing literature rather than new primary research findings.

This review article examines how BPC 157, a synthetic peptide derived from gastric juice, may provide cytoprotective effects that could theoretically address both hemorrhagic and thrombotic conditions through a unified mechanism (evidence level: review of human clinical, animal model, and in vitro studies). The authors synthesize existing literature suggesting BPC 157 promotes cellular protective mechanisms and vascular homeostasis, though the specific pathways and clinical applicability remain largely supported by preclinical evidence rather than robust human trials. The review highlights the potential therapeutic relevance of cytoprotective strategies but does not establish definitive clinical efficacy in human hemorrhage or thrombosis management.

This review article examines the use of growth factors and the stable gastric pentadecapeptide BPC 157 for treating injuries to tendons, ligaments, muscles, and their associated junctions with bone. The authors synthesize evidence from multiple research domains showing that BPC 157 exhibits angiogenic, anti-inflammatory, and tissue-regenerative properties in preclinical models of musculoskeletal injury. The evidence base includes human clinical studies, animal models, and in vitro research, though this is a literature review rather than original research.

This review article examined multiple classes of antiarrhythmic agents—including conventional Class I-IV antiarrhythmics, late sodium current inhibitors, potassium channel enhancers, ryanodine receptor stabilizers, gap junction modulators, atrial-selective agents, and the peptide BPC 157—and their proposed cytoprotective mechanisms in managing cardiac arrhythmias. The authors synthesized evidence suggesting these various drug classes may provide cardioprotection through different cellular pathways, though the review does not present new experimental data comparing efficacy. This is a **review article** synthesizing existing literature rather than original human clinical or experimental research.

This review article examines injectable peptide therapies, including BPC-157, relevant to orthopaedic and sports medicine practice, synthesizing existing evidence on mechanisms of action and clinical applications in musculoskeletal conditions. The review provides an overview of peptide-based therapeutic options and their potential role in orthopaedic treatment paradigms based on current literature. The evidence level is review article (synthesis of existing literature rather than original human clinical trials or animal model data).

This review article examines the current and potential applications of therapeutic peptides in orthopaedic medicine, including peptides such as BPC-157, discussing their mechanisms of action, clinical uses, and the obstacles to their development and implementation in orthopedic practice (Evidence level: Review). The article identifies key challenges in peptide therapeutics, such as stability, delivery mechanisms, and regulatory pathways, while also outlining future directions for research and clinical translation in orthopedic conditions. This represents a synthesis of existing literature rather than original research data from human clinical trials or animal studies.

This narrative review examined the evidence for BPC-157, a synthetic peptide derived from gastric juice, in promoting musculoskeletal tissue healing across multiple tissue types. The review identified promising preclinical findings in animal models showing potential benefits for tendon, ligament, muscle, and bone healing, though human clinical evidence remains limited and mostly anecdotal. The evidence base is primarily animal model and in vitro studies, with very few human clinical trials available to date.